The Effectiveness of Sovodak in the Treatment of Patients with Chronic Hepatitis C

Farshad  Talebian; Baran  Parhizkar; Behzad  Mohsenpour; Pezhman  Sharifi; Farshad  Sheikhesmaeili

doi:10.52981/sjms.v16i1.1102

Farshad Talebian Kurdistan University of Medical Sciences, Sanandaj
Baran Parhizkar Kurdistan University of Medical Sciences
Behzad Mohsenpour Kurdistan University of Medical Sciences
Pezhman Sharifi Kurdistan University of Medical Sciences
Farshad Sheikhesmaeili Kurdistan University of Medical Sciences

DOI: https://doi.org/10.52981/sjms.v16i1.1102

Keywords: Sovodak, hepatitis C, sustained virologic response, effectiveness,, liver cirrhosis

Abstract

Background: Recently, interferon-free treatment has been considered for the treatment of chronic hepatitis C due to their high therapeutic success and lack of serious side effects. The combination of Sofosbuvir and Daclatasvir is effective in the treatment of the disease because of its pan-genotype. In the present study, the effectiveness of Sovodak, which is a combination of the aforementioned two drugs in one tablet, in the treatment of patients with chronic hepatitis C and cirrhosis was investigated.
Methods: Patients with chronic hepatitis C whose diagnosis was confirmed by HCV RNA–PCR test were included in the study. These patients received one Sovodak tablet daily (for 12 weeks for non-cirrhotic patients and 24 weeks for cirrhotic patients). Sustained virologic response (SVR) was assessed by PCR test 12 weeks after the end of the treatment and one year later. Also, serum levels of liver enzymes, platelet count, and liver stiffness (using elastography method) were measured and their levels were compared before and after treatment in patients.
Results: Findings related to the PCR test in patients showed that the level of SVR was 100% in patients 12 weeks after treatment (SVR-12). In three cirrhotic patients who received only 12 weeks of drug treatment, the disease recurred a year later. According to the results, ALT and AST serum levels were significantly decreased (P < 0.001), and platelet count level was increased (P < 0.001) one year after the end of the treatment period. Also, the liver stiffness index measured using FibroScan was significantly decreased in patients 12 weeks after the end of the treatment (P < 0.001).
Conclusion: The results of this study, in line with other studies, showed the effective role of Sovodak in completely eliminating the HCV virus in patients with chronic hepatitis C. Cirrhotic patients need to receive treatment for at least six months.

References

[1] Lauer, G. M. and Walker, B. D. (2001). Hepatitis C virus infection. New England Journalof Medicine, vol. 345, no. 1, pp. 41–52.
[2] Manns, M. P., Buti, M., Gane, E., et al. (2017). Hepatitis C virus infection. NatureReviews Disease Primers, vol. 3, pp. 1–19.
[3] Merat, S., Rezvan, H., Nouraie, M., et al. (2010). Seroprevalence of hepatitis Cvirus: the first population-based study from Iran. International Journal of InfectiousDiseases, vol. 14, no. 3, pp. e113–e116.
[4] Hatzakis, A., Chulanov, V., Gadano, A., et al. (2015). The present and future diseaseburden of hepatitis C virus (HCV) infections with today’s treatmentparadigm–volume2. Journal of Viral Hepatitis, vol. 22, no. 1, pp. 26–45.
[5] Penin, F., Dubuisson, J., Rey, F. A., et al. (2004). Structural biology of hepatitis C virus.Hepatology, vol. 39, no. 1, pp. 5–19.
[6] Pawlotsky, J. M. (2002). Use and interpretation of virological tests for hepatitis C.Hepatology, vol. 36, no. 1, pp. s65–s73.
[7] Pawlotsky, J. M., Lonjon, I., Hezode, C., et al. (1998). What strategy should be usedfor diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology, vol.27, no. 6, pp. 1700–1702.
[8] Simmonds, P., Bukh, J., Combet, C., et al. (2005). Consensus proposals for a unifiedsystem of nomenclature of hepatitis C virus genotypes. Hepatology, vol. 42, no. 4,pp. 962–973.
[9] Hadziyannis, S. J., Sette, Jr., H., Morgan, T. R., et al. (2004). Peginterferon-α2a andribavirin combination therapy in chronic hepatitis C: a randomized study of treatmentduration and ribavirin dose. Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355.
[10] Jabari, H., Bayatian, A., Sharifi, A. H., et al. (2010). Safety and efficacy of locallymanufactured pegylated interferon in hepatitis C patients. Archives of IranianMedicine, vol. 13. no. 4, pp. 306–312.
[11] Hagan, L. M., Wolpe, P. R., and Schinazi, R. F. (2013). Treatment as prevention andcure towards global eradication of hepatitis C virus. Trends in Microbiology, vol. 21,no. 12, pp. 625–633.
[12] Samimi-Rad, K., Nategh, R., Malekzadeh, R., et al. (2004). Molecular epidemiologyof hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region.Journal of Medical Virology, vol. 74, no. 2, pp. 246–252.
[13]Sharifi,A.H.,HajSheykholeslami,A.,Poustchi,H.,etal(2016).Efficacyoflocallymanufacturedsofosbuviranddaclatasvir(Sovodak)incombinationwithribavirinintreatingpatientswithchronichepatitiscandcirrhosisinIranpreliminaryreport.Govaresh, vol. 21, pp. 93–97.
[14] Mehdipour, H., Moaddab, Y., Azizian, K., et al. (2019). Effects of 12-week treatmentwith Sovodak in patients infected by genotype 1 hepatitis C virus. Journal of Researchin Clinical Medicine, vol. 7, no. 1, pp. 1–6.
[15] Merat, S. (2020). SD1000: high sustained viral response rate in 1361 patients withhepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tabletof generic sofosbuvir and daclatasvir: a multicenter, phase III clinical trial. ClinicalInfectious Diseases, vol. 70, no. 10, pp. 2206–2212.
[16] Pol, S., Corouge, M., and Vallet-Pichard, A. (2016). Daclatasvir–sofosbuvir combinationtherapy with or without ribavirin for hepatitis C virus infection: from the clinicaltrials to real life. Hepatic Medicine: Evidence and Research, vol. 8, p. 21.
[17] Ji, D., Chen, G.-F., Wang, C., et al. (2016). Twelve-week ribavirin-free directactingantivirals for treatment-experienced Chinese with HCV genotype 1b infectionincluding cirrhotic patients. Hepatology International, vol. 10, no. 5, pp. 789–798.
[18] Welzel, T. M., Petersen, J., Herzer, K., et al. (2016). Daclatasvir plus sofosbuvir, withor without ribavirin, achieved high sustained virological response rates in patientswith HCV infection and advanced liver disease in a real-world cohort. Gut, vol. 65,no. 11, pp. 1861–1870.
[19] Ahmed, O. A., Safwat, E., Khalifa, M. O., et al. (2018). Sofosbuvir plus daclatasvir intreatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients:an experiment the size of Egyptian village. International Journal of Hepatology, vol.2018, aricle id. 9616234.
[20] Abdel-Moneim, A., Aboud, A., Abdel-Gabaar, M., et al. (2018). Efficacy and safety ofsofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patientswith chronic hepatitis C genotype 4. Hepatology International, vol. 12, no. 4, pp.348–355.
[21] Omar, H., El Akel, W., Elbaz, T., et al. (2018). Generic daclatasvir plus sofosbuvir,with or without ribavirin, in treatment of chronic hepatitis C: real-world results from18,378 patients in Egypt. Alimentary Pharmacology & Therapeutics, vol. 47, no. 3,pp. 421–431.
[22] Nelson, D. R., Cooper, J. N., Lalezari, J. P., et al. (2015). All-oral 12-week treatment withdaclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study. Hepatology, vol. 61, no. 4, pp. 1127–1135.
[23] Merat, S., Sharifi, A. H., Haj-Sheykholeslami, A., et al. (2017). The efficacy of 12 weeksof sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis,genotypes 1 and 3. Hepatitis Monthly, vol. 17, no. 1, p. e44564.
[24] Leroy, V., Angus, P., Bronowicki, J. P., et al. (2016). Daclatasvir, sofosbuvir, and ribavirinfor hepatitis C virus genotype 3 and advanced liver disease: a randomized phase IIIstudy (ALLY-3+). Hepatology, vol. 63, no. 5, pp. 1430–1441.
[25] Hung, C. H., Lee, C. M., Lu, S. N., et al. (2006). Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients withhepatitis C virus-related cirrhosis. Journal of Viral Hepatitis, vol. 13, no. 6, pp. 409–414.
[26] Kasahara, A., Tanaka, H., Okanoue, T., et al. (2004). Interferon treatment improvessurvival in chronic hepatitis C patients showing biochemical as well as virologicalresponses by preventing liver-related death. Journal of Viral Hepatitis, vol. 11, no. 2,pp. 148–156.
[27] Veldt, B., Saracco, G., Boyer, N., et al. (2004). Long term clinical outcome of chronichepatitis C patients with sustained virological response to interferon monotherapy.Gut, vol. 53, no. 10, pp. 1504–1508.
[28] Maylin, S., Martinot–Peignoux, M., Moucari, R., et al. (2008). Eradication of hepatitisC virus in patients successfully treated for chronic hepatitis C. Gastroenterology, vol.135, no. 3, pp. 821–829.
[29] Mallet, V., Gilgenkrantz, H., Serpaggi, J., et al. (2008). Brief communication: therelationship of regression of cirrhosis to outcome in chronic hepatitis C. Annals ofInternal Medicine, vol. 149, no. 6, pp. 399–403.
[30] D’Ambrosio, R., Aghemo, A., Rumi, M. G., et al. (2012). A morphometric andimmunohistochemical study to assess the benefit of a sustained virological responsein hepatitis C virus patients with cirrhosis. Hepatology, vol. 56, no. 2, pp. 532–543.
[31] George, S. L., Bacon, B. R., Brunt, E. M., et al. (2009). Clinical, virologic, histologic,and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150patients. Hepatology, vol. 49, no. 3, pp. 729–738.
[32] Shiha, G., Soliman, R., Mikhail, N., et al. (2020). Changes in hepatic fibrosis stagesafter achieving SVR following direct-acting anti-viral treatment: a prospective study.GastroHep, vol. 2, no. 1, pp. 39–48.